HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Jan Skokowski Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jassem, J. Articles by Roszkiewicz, A. Search for Related Content PubMed PubMed Citation Articles by Jassem, J. Articles by Roszkiewicz, A.

J Thorac Cardiovasc Surg 2000;119:1141-1146
© 2000 The American Association for Thoracic Surgery

GENERAL THORACIC SURGERY

RESULTS OF SURGICAL TREATMENT OF NON–SMALL CELL LUNG CANCER: VALIDATION OF THE NEW POSTOPERATIVE PATHOLOGIC TNM CLASSIFICATION

Jacek Jassem, MD^a, Jan Skokowski, MD^b, Rafa Dziadziuszko, MD^a, Ewa Jassem, MD^c, Amelia Szymanowska, BSc^c, Witold Rzyman, MD^b, Andrzej Roszkiewicz, MD^d

From the Departments of Oncology and Radiotherapy,^a Thoracic Surgery,^b Pneumonology,^c and Pathology,^d Medical University of Gdask, Poland.

Address for reprints: Jacek Jassem, MD, Department of Oncology and Radiotherapy, Medical University of Gdask, 7 Dçebinki St, 80-211 Gdask, Poland (E-mail: jjassem{at}amedec.amg.gda.pl ).

Objective: Prognostic relevance of the current TNM stage grouping for lung cancer is still a matter of debate.
Methods: To validate the new pathologic TNM classification for non–small cell lung cancer, we analyzed the survival data of 586 patients who underwent complete pulmonary resection and pathologic staging at one institution.
Results: The current TNM stage grouping well reflected the long-term prognostic hierarchy. There was a good distinction between new substages IA and IB (5-year survivals of 66% and 53%, respectively). The subdivision of stage II led to an under-representation of stage IIA (6 patients [1.0%]), and therefore the appropriateness of this modification could not be verified. Five-year survival in the T3 N0 category (30%) was significantly better than that found in the new stage IIIA (15%). No difference was found between T3 N0 and T2 N1, the categories constituting new stage IIB. Within stage IIIA there was a significant survival difference between T3 N2 (6%) and the remaining T and N designations (18%). Moreover, the 5-year survival in the T3 N1 category (35%) was similar to that found in the new stage IIB (27%) and better than in any T N2 tumors (12%).
Conclusion: Most of our findings confirmed prognostic relevance of the current pTNM stage grouping in patients with resectable non–small cell lung cancer. However, despite recent modifications, there is still a significant heterogeneity that flaws stage IIIA.

This article has been cited by other articles:

				C.-Y. Wang, Y.-S. Lin, C. Tzao, H.-C. Lee, M.-H. Huang, W.-H. Hsu, and H.-S. Hsu Comparison of Charlson comorbidity index and Kaplan Feinstein index in patients with stage I lung cancer after surgical resection Eur. J. Cardiothorac. Surg., December 1, 2007; 32(6): 877 - 881. [Abstract] [Full Text] [PDF]

				T. Tsuchiya, S. Hashizume, S. Akamine, M. Muraoka, S. Honda, K. Tsuji, S. Urabe, T. Hayashi, N. Yamasaki, and T. Nagayasu Upstaging by Vessel Invasion Improves the Pathology Staging System of Non-Small Cell Lung Cancer Chest, July 1, 2007; 132(1): 170 - 177. [Abstract] [Full Text] [PDF]

				H. Asamura, T. Goya, Y. Koshiishi, Y. Sohara, R. Tsuchiya, E. Miyaoka, and The Japanese Joint Committee of Lung Cancer Regist How should the TNM staging system for lung cancer be revised? A simulation based on the Japanese Lung Cancer Registry populations. J. Thorac. Cardiovasc. Surg., August 1, 2006; 132(2): 316 - 319. [Abstract] [Full Text] [PDF]

				Bronchogenic Carcinoma Cooperative Group of the Sp Survival of 2,991 Patients With Surgical Lung Cancer: The Denominator Effect in Survival Chest, October 1, 2005; 128(4): 2274 - 2281. [Abstract] [Full Text] [PDF]

				S.-i. Takeda, S. Fukai, H. Komatsu, E. Nemoto, K. Nakamura, M. Murakami, and Japanese National Chest Hospital Study Group Impact of Large Tumor Size on Survival After Resection of Pathologically Node Negative (pN0) Non-Small Cell Lung Cancer Ann. Thorac. Surg., April 1, 2005; 79(4): 1142 - 1146. [Abstract] [Full Text] [PDF]

				A. Lopez-Encuentra, R. Garcia-Lujan, J. Jose Rivas, J. Rodriguez-Rodriguez, J. Torres-Lanza, G. Varela-Simo, and Bronchogenic Carcinoma Cooperative Group of the Sp Comparison Between Clinical and Pathologic Staging in 2,994 Cases of Lung Cancer Ann. Thorac. Surg., March 1, 2005; 79(3): 974 - 979. [Abstract] [Full Text] [PDF]

				T. Berghmans, A. P. Meert, B. Martin, V. Ninane, and J. P. Sculier Prognostic role of epidermal growth factor receptor in stage III nonsmall cell lung cancer Eur. Respir. J., February 1, 2005; 25(2): 329 - 335. [Abstract] [Full Text] [PDF]

				J. E. Castelao, R. D. Bart III, C. A. DiPerna, E. M. Sievers, and R. M. Bremner Lung cancer and cyclooxygenase-2 Ann. Thorac. Surg., October 1, 2003; 76(4): 1327 - 1335. [Abstract] [Full Text] [PDF]

				W. J. Scott, J. Howington, and B. Movsas Treatment of Stage II Non-small Cell Lung Cancer Chest, January 1, 2003; 123(1_suppl): 188S - 201S. [Abstract] [Full Text] [PDF]

				S. G. Spiro and J. C. Porter Lung Cancer--Where Are We Today?: Current Advances in Staging and Nonsurgical Treatment Am. J. Respir. Crit. Care Med., November 1, 2002; 166(9): 1166 - 1196. [Abstract] [Full Text] [PDF]